Don
Because the US sank billions of $ into silicon integration and microchip development and perhaps the most important aspect, miniturisation, for control and guidance systems.How?
Because the US sank billions of $ into silicon integration and microchip development and perhaps the most important aspect, miniturisation, for control and guidance systems.How?
Nothing more than a front for big pharma, their sole purpose is to stop cheap, reliable miracle cures like this from ever getting to market...
Nothing more than a front for big pharma, their sole purpose is to stop cheap, reliable miracle cures like this from ever getting to market...
However, because the clinical use of DCA has been associated with peripheral nerve toxicity (28, 29), the clinical efficacy and toxicity profile of DCA as an anticancer agent will have to be carefully examined in clinical trials. If this toxicity can be tolerated and its efficacy demonstrated, DCA treatment may be an important example of anticancer intervention through metabolic targeting. Although the above observations offer hope for a relatively simple and cost-effective way of specifically killing cancer cells by targeting their metabolism, the situation is likely to be more complicated in practice. [Section explaining that this chemical targets the pathway cells use to get energy from glucose, and that many cancers appear to be able to use alternative pathways.] Indeed, it has been documented that cancer cells can switch metabolic pathways or energy sources in response to nutrient depletion or fuel source limitation (36). Thus,
the targeting of a single metabolic pathway, such as inhibiting glycolysis, may not be sufficient to eliminate tumor cells. Given the heterogeneity of human tumors and the instability of cancer cell genomes, a major challenge to the metabolic targeting strategy may be potential resistance to a single antimetabolic drug. Combination therapies that block multiple metabolic pathways should therefore be considered in both preclinical “proof of principle” trials and in clinical settings.
Not sure if serious.
This is old news. The pharmaceutical companies are unwilling to sponsor because the drug can't be patented IIRC.
http://scienceblog.cancerresearchuk.org/2010/05/12/potential-cancer-drug-dca-tested-in-early-trials/
There's no money in a cure
there is buckets and buckets of money in cancer research just from charities. If it is promising and pharmac'ls won't pick up, then one of the charities definitely will/would have.
Genuine or not the drug companies are not interested in cures for anything they wouldn't sell drugs if they found cures.
I don't take antibiotics they destroy the immune system, thus making you more prone to sickness a nice side effect as the pharma make more money.What about vaccines and antibiotics, for example
I remember this ages ago, didn't it need something like direct application or huge concentrations and wouldn't work outside of a petri dish and inside a person.
But equally if this is so cheap and effective as they claim why hasn't one of the NPOs or cancer research charities funded it?